NEW YORK (GenomeWeb News) – Arno Therapeutics today announced it has inked an exclusive, worldwide licensing deal with the University of Minnesota for a technology covering a gene expression signature derived from archived breast cancer tissue samples.

As part of the deal, Arno will continue development of a progesterone receptor gene signature as a potential companion diagnostic for anti-progestins, including Arno's lead compound called onapristone for treating men's and women's cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.